Glenmark Pharmaceuticals launches TEVIMBRA in India

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Globally, BRUKINSA is approved in more than 70 countries

Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr

Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore

Glenmark launches nutrition program to fight malnutrition in Philippines

This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M

Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore

Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India

Glenmark released Picture Post Cards on World Vitiligo Day

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million